UBS Knock-Out BIIB/ DE000UM4R5U1 /
2024-05-15 7:38:21 PM | Chg.+0.100 | Bid9:29:19 PM | Ask9:29:19 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.400EUR | +33.33% | 0.390 Bid Size: 100,000 |
0.410 Ask Size: 100,000 |
Biogen Inc | 193.1495 USD | 2078-12-31 | Call |
GlobeNewswire
1:33 AM
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
04-29
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
03-11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...